Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

The disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.

Amid rising risks, I favor high-yield stocks with strong business models. Check out the stock picks that offer stability, ...

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...

The stock market's performance in the coming year feels less certain than usual. Luckily, there's a well-established, ...

Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...

Pfizer has finalized the sale of its entire holding in Haleon , generating approximately 2.5 billion ($3.24 billion), Reuters ...

Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.